RegisterLogin

Tariquidar

CAT: 0804-HY-10550-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-10550-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Tariquidar (XR9576) is a potent and specific inhibitor of P-glycoprotein (P-gp) with the high affinity (Kd=5.1 nM) [1].
CAS Number
[206873-63-4]
Product Name Alternative
XR9576
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
P-glycoprotein
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Tariquidar.html
Purity
99.45
Solubility
H2O : < 0.1 mg/mL
Smiles
O=C(C1=CC2=CC=CC=C2N=C1)NC3=CC(OC)=C(OC)C=C3C(NC4=CC=C(CCN5CC6=C(C=C(OC)C(OC)=C6)CC5)C=C4)=O
Molecular Formula
C38H38N4O6
Molecular Weight
646.73
Precautions
H302, H315, H319, H335
References & Citations
[1]Martin C, et al. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol, 1999, 128 (2), 403-411.|[2]Mistry P, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res, 2001, 61 (2), 749-758.|[3]Zimmermann ES, et al. Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration. Antimicrob Agents Chemother. 2015 Nov 30;60 (2) :946-54.|[4]Kao YH, et al. Regulation of P-glycoprotein expression in brain capillaries in Huntington's disease and its impact on brain availability of antipsychotic agents risperidone and paliperidone. J Cereb Blood Flow Metab. 2016 Aug;36 (8) :1412-23.|[5]Matzneller P, et al. Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration. Eur J Drug Metab Pharmacokinet. 2018 Apr 3.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Citation 01
ACS Chem Neurosci. 2025 Sep 3;16 (17) :3340-3353.|Antimicrob Agents Chemother. 2015 Nov 30;60 (2) :946-54. |Antioxidants (Basel) . 2021 Jun 11;10 (6) :949.|Antiviral Res. 2021 Sep:193:105124.|bioRxiv. 2025 Jun 24:2025.06.18.660465.|bioRxiv. 2025 Sep 20.|Cell Death Discov. 2021 Aug 5;7 (1) :204.|Cell. 2023 Dec 7;186 (25) :5500-5516.e21.|Commun Chem. 2024 Jul 13;7 (1) :158.|Crit Rev Anal Chem. 2022;52 (7) :1557-1571.|Eur J Drug Metab Pharmacokinet. 2018 Oct;43 (5) :599-606.|Eur J Med Chem. 2017 Feb 15:127:586-598.|Eur J Med Chem. 2018 Mar 10:147:7-20.|Eur J Pharm Sci. 2019 Jan 15:127:319-329.|Eur J Pharmacol. 2024 Apr 15:969:176431.|Hepatol Commun. 2024 May 2;8 (5) :e0437.|Int J Mol Sci. 2022 Nov 29;23 (23) :14948.|Int J Mol Sci. 2023 Mar 10;24 (6) :5298.|J Biomed Nanotechnol. 2018 Oct 1;14 (10) :1705-1718.|J Cereb Blood Flow Metab. 2016 Aug;36 (8) :1412-23. |J Cereb Blood Flow Metab. 2021 Jul;41 (7) :1634-1646.|J Control Release. 2022 Sep:349:109-117.|J Drug Deliv Sci Technol. May 2022, 103323.|J Nanopart Res. (2018) 20:176.|J Nat Prod. 2022 Dec 23;85 (12) :2746-2752.|Langmuir. 2015 May 12;31 (18) :5115-22. |Mar Drugs. 2022 Nov 25;20 (12) :738.|Mar Drugs. 2022 Sep 23;20 (10) :597.|Mar Drugs. 2023 Jan 14;21 (1) :54.|Mar Drugs. 2023 Mar 14;21 (3) :178.|Mar Drugs. 2024 Aug 30;22 (9) :396.|Mol Pharm. 2019 Mar 4;16 (3) :1282-1293.|Mol Pharm. 2021 Jan 4;18 (1) :416-428.|Pharm Res. 2017 Jan;34 (1) :148-160.|Pharmaceuticals (Basel) . 2023 Feb 24;16 (3) :349.|Pharmaceutics. 2021 Feb 26;13 (3) :306.|PLoS One. 2017 Sep 15;12 (9) :e0183662. |Res Sq. 2025 May 16.|Research Square Preprint. 2021 Mar.|Research Square Preprint. 2024 Feb 6.|Research Square Print. 2022 Jul.|RSC Adv. 2016,6, 69083-69093.|Sci Bull. 2016 Apr;61 (7) :552-560.|Sci Rep. 2017 Dec 22;7 (1) :18069.|Sci Rep. 2022 Aug 9;12 (1) :13570.|Small. 2020 Nov;16 (44) :e2004172.|Xenobiotica. 2020 Mar;50 (3) :354-362.|J Cereb Blood Flow Metab. 2020 Jan;40 (1) :150-162.|Mol Imaging Biol. 2019 Apr;21 (2) :257-268. |Mol Pharm. 2020 Sep 8;17 (9) :3477-3486.|Nucl Med Biol. 2018 May:60:29-36.|RWTH Aachen University. 2021 Oct.|J Control Release. 2022 Feb:342:44-52.

Related Products

CatalogName

Alternative Products

CatalogName
202820Tariquidar
MBS5786050Tariquidar dimesylate
166676Tariquidar-d4
MBS5814652Tariquidar dihydrochloride
MBS386430-01Tariquidar (XR9576)
M15368-01Tariquidar methanesulfonate hydrate
MBS5754009Tariquidar methanesulfonate, hydrate

Popular Products